DARK Classics in Chemical Neuroscience: Ibogaine
- PMID: 30216039
- DOI: 10.1021/acschemneuro.8b00294
DARK Classics in Chemical Neuroscience: Ibogaine
Abstract
The West African iboga plant has been used for centuries by the Bwiti and Mbiri tribes to induce hallucinations during religious ceremonies. Ibogaine, the principal alkaloid responsible for iboga's psychedelic properties, was isolated and sold as an antidepressant in France for decades before its adverse effects precipitated its removal from the market. An ibogaine resurgence in the 1960s was driven by U.S. heroin addicts who claimed that ibogaine cured their opiate addictions. Behavioral pharmacologic studies in animal models provided evidence that ibogaine could blunt self-administration of not only opiates but cocaine, amphetamines, and nicotine. Ibogaine displays moderate-to-weak affinities for a wide spectrum of receptor and transporter proteins; recent work suggests that its actions at nicotinic acetylcholine receptor subtypes may underlie its reputed antiopiate effects. At micromolar levels, ibogaine is neurotoxic and cardiotoxic and has been linked to several deaths by cardiac arrest. Structure-activity studies led to the isolation of the ibogaine analog 18-methoxycoronaridine (18-MC), an α3β4 nicotinic receptor modulator that retains ibogaine's anticraving properties with few or no adverse effects. Clinical trials of 18-MC treatment of nicotine addiction are pending. Ibogaine analogs may also hold promise for treating anxiety and depression via the "psychedelic-assisted therapy" approach that employs hallucinogens including psilocybin and methylenedioxymethamphetamine ("ecstasy").
Keywords: addiction; hallucinogen; iboga; nicotine; opioid; therapeutic.
Similar articles
-
Ibogaine in the treatment of substance dependence.Curr Drug Abuse Rev. 2013 Mar;6(1):3-16. doi: 10.2174/15672050113109990001. Curr Drug Abuse Rev. 2013. PMID: 23627782 Review.
-
Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.Brain Res. 1998 Aug 3;800(2):260-8. doi: 10.1016/s0006-8993(98)00527-7. Brain Res. 1998. PMID: 9685673
-
Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.Prog Brain Res. 2018;242:217-257. doi: 10.1016/bs.pbr.2018.08.005. Epub 2018 Oct 12. Prog Brain Res. 2018. PMID: 30471681 Review.
-
Development of novel medications for drug addiction. The legacy of an African shrub.Ann N Y Acad Sci. 2000;909:88-103. doi: 10.1111/j.1749-6632.2000.tb06677.x. Ann N Y Acad Sci. 2000. PMID: 10911925
-
18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats.Brain Res. 1996 May 6;719(1-2):29-35. doi: 10.1016/0006-8993(96)00056-x. Brain Res. 1996. PMID: 8782860
Cited by
-
Substance Addiction Rehabilitation Drugs.Pharmaceuticals (Basel). 2024 May 10;17(5):615. doi: 10.3390/ph17050615. Pharmaceuticals (Basel). 2024. PMID: 38794185 Free PMC article. Review.
-
Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.Psychopharmacology (Berl). 2024 May 14. doi: 10.1007/s00213-024-06599-5. Online ahead of print. Psychopharmacology (Berl). 2024. PMID: 38743110 Review.
-
Exploring Novel Antidepressants Targeting G Protein-Coupled Receptors and Key Membrane Receptors Based on Molecular Structures.Molecules. 2024 Feb 22;29(5):964. doi: 10.3390/molecules29050964. Molecules. 2024. PMID: 38474476 Free PMC article. Review.
-
5-HT2A Receptor Knockout Mice Show Sex-Dependent Differences following Acute Noribogaine Administration.Int J Mol Sci. 2024 Jan 5;25(2):687. doi: 10.3390/ijms25020687. Int J Mol Sci. 2024. PMID: 38255760 Free PMC article.
-
Magnesium-ibogaine therapy in veterans with traumatic brain injuries.Nat Med. 2024 Feb;30(2):373-381. doi: 10.1038/s41591-023-02705-w. Epub 2024 Jan 5. Nat Med. 2024. PMID: 38182784 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources